SCIENTISTS in Scotland have identified genetic changes that may predict the likelihood of breast cancer relapse in women who take a common type of hormone therapy.
It is believed the findings could help to identify those at risk so they can be given alternative treatments which could lower the chances of developing incurable secondary breast cancer.
Researchers at the University of Edinburgh studied tumour samples from patients who had been taking aromatase inhibitor for up to two years. None of the patients had undergone surgery to remove their tumours.
Changes to “chemical signatures” during the work suggest it may be possible to predict which women are likely to relapse.
Dr Andy Sims, of the MRC Institute of Genetics and Molecular Medicine, said: “Treatment resistance is hard to study and laboratory experiments often do not closely resemble the situation
in patients.
“This is the first time we have been able to investigate genetic changes in individual patients’ tumours over time.
“We hope the findings will help to develop new tests that predict which women on hormone therapy are likely to relapse so that they can be offered alternative treatments.”
Tumour samples were taken before the women started hormone therapy, within the first few weeks and after four months of treatment. This allowed the scientists to see how treatment affected the tumours over time.
They found hormone therapy almost immediately triggered changes in the genes that were switched on in the tumours. These differences became more pronounced over time.
Subtle differences were seen in the changes that occurred in women whose cancer had become resistant to treatment.
Chemical signatures, called epigenetic changes, were absent in tumours that developed resistance to hormone therapy but were present in those that had started growing again, after shrinking initially.
These differences were present in the first weeks of hormone therapy and scientists say it suggests it may be possible to predict which women are likely to relapse.
Dr Simon Vincent, director of research at charity Breast Cancer Now, which helped fund the study, said: “It’s really encouraging that this study has identified epigenetic changes that may help predict which patients are more likely to see their cancer come back.
“We hope further research will now help to identify exactly when these changes may begin to appear and find ways to target them, enabling us to intervene at the right time.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here